Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve Meeting Abstract
| Authors: | Chia, S. K. L.; Ruiz-Borrego, M.; Drullinsky, P.; Juric, D.; Bachelot, T.; Rugo, H. S.; Ciruelos, E. M.; Lerebours, F.; Prat, A.; Akdere, M.; Arce, C.; Gu, E.; Turner, N. C. |
| Abstract Title: | Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120600165 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.1060 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1060 -- Source: Wos |
